Cellceutix Inc.'s chief medical officer Daniel Jorgenson told BioWorld Today that "momentum was growing" with brilacidin against acute bacterial skin and skin structure infection (ABSSSI) at Polymedix Inc. before the firm went bankrupt in 2013 and sold off its assets.